HUBBARD, OH--(Marketwired - Dec 21, 2015) - NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce that they have been contracted by one of the world's three largest global Medical Device manufacturers to customize the NanoLogix N-Assay, a unique modified ELISA diagnostic.

NanoLogix was contacted by the company in February of 2015 and the agreement was finalized in late October with a purchase order issued in late November. NanoLogix began the initial customization of the N-Assay in December, with the client billed for one-third of the contract amount. The identity of the client and further details will remain confidential as per contract restrictions until such time as NanoLogix may be permitted to comment.

The N-Assay provides extraordinarily rapid, accurate, and sensitive detection and identification of any bacteria tested to date for which there exists an antibody, with the added capability of near-simultaneous determination of antibiotic sensitivity and resistance.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on both rapid diagnostics and petri plates. Its products offer accelerated detection and identification of microorganisms. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.

For more information visit:

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information:


NanoLogix, Inc.
Carol Surrena